AstraZeneca's $5bn drug promise is no 'buy' signal for Deutsche

finance.yahoo.com · 2026-09-10

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) drew praise from Deutsche Bank for tozorakimab's lung disease data, but the broker paired its positive assessment with a bearish verdict on the shares. The shares traded at 11,634p, broadly flat, while the bank rated the drugmaker 'sell' with a target...

Read the full story at finance.yahoo.com →